Article summary
Resilient Pharmaceuticals has resubmitted its New Drug Application for MDMA-assisted therapy for PTSD, without the new Phase 3 trial the FDA asked for. Canada funds a C$24 million cannabis and brain health consortium, and Definium's oral LSD tablet clears Phase 3 in generalized anxiety disorder. The post Weekly Psychedelic Policy Briefing β August 16, 2026 appeared first on Psychedelics Today.
Continue to the original publication for the complete article.